In the rapidly evolving landscape of biopharmaceutical development, few modalities have generated as much excitement—or analytical complexity—as antibody-drug conjugates (ADCs). Often described as "three-in-one" therapeutics, these sophisticated constructs combine the targeted precision of a monoclonal antibody (mAb), a highly potent cytotoxic payload, and a specialized chemical linker.
While this tripartite design offers unparalleled therapeutic potential, it introduces extraordinary analytical challenges. Characterizing these highly heterogeneous molecules demands separation strategies that push far beyond traditional chromatographic limits.
To explore how advanced chromatography and hyphenated techniques are reshaping ADC workflows, we spoke with Hongyue Guo, Principal Research Scientist II at AbbVie. Guo shares insights on resolving the drug-to-antibody ratio (DAR), overcoming critical chemistry, manufacturing, and controls (CMC) bottlenecks, and balancing cutting-edge development tools with the practical demands of routine quality control (QC).
The Multidimensional Search for the True DAR
At the heart of any ADC characterization program lies the DAR—a critical quality attribute (CQA) that directly governs both therapeutic efficacy and patient safety. Historically, defining this ratio relied on basic hydrophobic interaction chromatography (HIC). However, as payloads grow more hydrophobic and conjugation chemistries become more complex, traditional columns are struggling to keep pace.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
"The latest progress in this space is driven by next-generation HIC columns," explains Guo. "These columns offer significantly higher efficiency, faster baseline separation, and improved hydrophobic selectivity. But columns alone are no longer a silver bullet."
To truly unlock complex DAR profiles, analytical laboratories are increasingly pairing these advanced columns with multidimensional setups. Recent HIC column innovations focus on smaller nonporous particles, bioinert supports, and carefully tuned ligand chemistries to minimize nonspecific adsorption, preserve native recovery, and deliver the selectivity required to resolve heterogeneous ADC drug-load species.
"When you combine next-generation HIC columns with multidimensional workflows—such as reversed-phase/size-exclusion chromatography (RP/SEC) with mass spectrometry (MS) confirmation—you build a remarkably robust toolset," Guo describes. "These hyphenated configurations dramatically improve the resolution of closely spaced DAR species, making characterization highly reliable even for the most complex ADC architectures."
Conquering Hydrophobic and Heterogeneous Modalities
A recurring obstacle in ADC analysis is that highly hydrophobic drug-linker combinations do not always behave predictably on a column. High-affinity hydrophobic species can stick to stationary phases, leading to poor recovery, co-elution of distinct species, and a high density of unresolved positional isomers.
"The core issue is that hydrophobic and highly heterogeneous ADCs can easily be misrepresented by chromatography alone," Guo warns. "If you rely solely on standard UV-chromatographic peaks, issues like sample loss on the column or co-eluting isomers will skew your average DAR calculation, masking the true nature of the sample."
To address this vulnerability, modern analytical strategies must shift away from single-dimension separations toward hybrid workflows that preserve the structural integrity of the conjugate.
"We resolve this by combining HIC or RP with native MS, multidimensional chromatography, and middle-up LC-MS workflows," he notes. "This hybrid approach is highly effective because it preserves the molecule's native distribution during the initial separation, while simultaneously providing intact, subunit, and conjugate site-level views of the drug load distribution."
Overcoming CMC Bottlenecks and Trace Impurities
During CMC development, developers must build a comprehensive control strategy that can withstand intense regulatory scrutiny.
"A major limitation of traditional chromatography in ADC CMC is that it captures only part of the heterogeneity story," Guo summarizes. "While it can estimate the average DAR distribution, it often falls short when trying to fully resolve positional isomers, site occupancy, or linker-payload cleavage. Because of these blind spots, orthogonal LC-MS-based strategies have transitioned from luxury characterization tools to essential CMC necessities."
To illustrate this, Guo points to a critical safety requirement: the detection and quantification of trace levels of free, unconjugated cytotoxic drug residues. Unbound payloads pose severe systemic toxicity risks to patients, requiring detection limits in the low picogram range.
"The most reliable platforms for trace free-drug quantification are multidimensional LC-MS methods, particularly online SEC ✕ RP-MS," he explains. "These configurations significantly outperform traditional UV-based assays. By combining online sample cleanup, highly orthogonal
separation, and mass-selective detection, they provide the extreme sensitivity and specificity required to measure free payloads and their degradation products at trace levels within highly complex, protein-rich ADC matrices."
Harmonizing the Data: A Case Study in Product Understanding
Implementing a suite of advanced, highly sensitive instruments can sometimes backfire if the resulting data streams appear to contradict one another. Guo recalls a memorable development project where introducing high-resolution analytics completely transformed his team's perspective.
"We had a sample that presented what appeared to be an acceptable average DAR by traditional chromatography," Guo recalls. "However, when we analyzed the same batch using native MS and middle-up LC-MS, we discovered that the sample actually possessed an unexpectedly broad drug-load distribution. The seemingly perfect 'average' was actually a highly heterogeneous mixture."
This discovery forced a fundamental pivot in the team's control strategy. "That revelation completely changed our development approach," he says. "We shifted our focus away from managing a single, average DAR number. Instead, we moved toward controlling the full distribution, conjugation behavior, and structural integrity as a connected CQA set using complementary orthogonal methods."
When asked how laboratories can prevent these highly sensitive, complementary methods from generating conflicting results, Guo emphasizes the importance of changing one's analytical mindset.
"The goal is not forcing every single method to agree numerically," he explains. "Instead, it is ensuring they converge on the same product understanding. In ADCs, disagreements usually come from comparing methods with different selectivities, recoveries, or definitions of what they quantify, rather than the sample itself. The best way to avoid conflicting results is to build a method hierarchy up front, so each assay answers a different question and all are tied to a single reference material and common data model."
Scaling Down: Bridging Development with the QC Floor
Achieving a high-resolution, multi-attribute understanding of an ADC in a development lab is a massive milestone. However, the true test of a molecule's clinical viability lies in how easily that analytical understanding can be packaged and transferred to a routine, highly regulated quality control environment.
"For ADCs, I do not try to force every cutting-edge assay into QC," Guo asserts. "Instead, I ask which data are essential for release, stability, or comparability, and which data are better kept as characterization tools. You must run this filter early."
According to Guo, the secret to robust method transfer is utilizing advanced characterization to establish limits, and then simplifying the operational workflow for routine execution.
"We balance innovation and robustness by using advanced chromatographic tools in development to define the product's critical behavior, then simplifying and locking the final QC method around the essential control points," he outlines. "The goal is not to move the most sophisticated method into routine QC, but to transfer the scientific understanding into a method that is rugged, reproducible, and platform-independent."
The Next Frontier: SEC-MALS
Looking ahead, Guo believes the industry is on the cusp of adopting a new primary analytical tool that could streamline current workflows.
"I think the next major step-change will be SEC-MALS," he predicts. "It has real potential in ADC characterization because it provides a native, label-free measure of intact mass, DAR, aggregation, and fragmentation in a single workflow. It is especially valuable as an orthogonal platform to HIC and LC-MS, though it works best as a complement rather than a replacement for methods that resolve detailed drug-load heterogeneity."
